New hope for brain tumor patients: experimental drug targets recurrent meningioma

NCT ID NCT07533942

First seen Apr 17, 2026 · Last updated May 09, 2026 · Updated 4 times

Summary

This study tests an experimental drug called JZP3507 in 30 adults with recurrent grade 2 or 3 meningioma, a type of brain tumor. Participants take the drug orally to see if it can shrink or control the tumor. The goal is to find a new treatment option for people who have not responded to standard therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Louisiana State University

    New Orleans, Louisiana, 70112, United States

  • Mass General

    Boston, Massachusetts, 02114, United States

  • NYU- Langone Health

    New York, New York, 10016, United States

  • Sutter Health

    San Francisco, California, 94109, United States

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.